the team took the spike protein from sars-cov-2 and put it on an adenovirus. then they injected that virus into test patients. the idea is that the patients' immune systems will learn to attack the spike protein no matter what virus it is on. this vaccine completed phase i trials and as of july 2020 is entering phase iii trials. the vaccine is called chadox1 ncov-19.